Semaglutide may lower uric acid, but it isn't an established treatment for gout. The evidence on semaglutide and gout is mixed, and lower blood levels haven't been shown to mean fewer attacks. Flares have also been reported during substantial weight loss.
Uric acid is a waste product made when the body breaks down natural substances in food and its own cells. Its blood form is usually called urate in studies. Gout happens when urate forms crystals in joints, causing painful swelling.
What the evidence says about semaglutide and gout
Semaglutide belongs to the GLP-1 medicine family, which mimics a gut hormone involved in appetite and blood sugar. Ozempic and Wegovy are semaglutide brands.
A 2024 study in Clinical Therapeutics followed medical records for five years. It was observational: researchers compared treatment groups without assigning medicines. GLP-1 users had no clear reduction in new gout diagnoses compared with matched people receiving metformin or insulin, other diabetes medicines.
SGLT2 inhibitors, a different diabetes medicine family that helps the kidneys pass sugar into urine, were associated with fewer gout diagnoses than GLP-1 medicines.
The study reported hazard ratios, which compare the rate of new events over time. Numbers below 1 favored SGLT2 medicines here. A 95% confidence interval describes the statistical uncertainty around each estimate.
| Background diabetes treatment | SGLT2 versus GLP-1 hazard ratio | 95% confidence interval |
|---|---|---|
| Metformin | 0.77 | 0.70–0.86 |
| Insulin | 0.82 | 0.73–0.91 |
Those comparisons do not establish that GLP-1 medicines cause gout. Treatment groups can still differ in ways that medical records don't capture.
Does Wegovy lower uric acid?
The most directly relevant semaglutide findings come from tablets. The URISEMA study, published in Seminars in Arthritis and Rheumatism in 2025, followed 236 adults with type 2 diabetes receiving oral semaglutide.
After 12 months, uric acid fell by an average of 0.2 mg/dL, the unit used on many blood tests. Among people starting above 6 mg/dL, the average decrease was 0.8 mg/dL.
The study had no randomly assigned comparison group, and many participants also used SGLT2 medicines. It cannot isolate semaglutide's contribution. It also doesn't establish that Wegovy or Ozempic injections prevent gout attacks.
The newer findings on GLP-1 gout risk
As of September 30, 2026, the day this article was written, a September 18 report from study authors in AAOS Now adds a caution. The authors compared two matched groups of 73,483 adults with obesity and type 2 diabetes.
Over five years, gout was recorded in about 74 per 1,000 GLP-1 users versus 66 per 1,000 nonusers: 7.4% versus 6.6%. The reported relative risk, a comparison of those proportions, was 1.12; the absolute difference was about eight additional diagnoses per 1,000 people.
This was an observational report about the medicine family, so it doesn't establish semaglutide's individual effect. Prescription records don't confirm actual use, and differences between patients can influence the results.
A February 2026 review of 43 randomized trials, studies with random treatment assignment, found no clear difference in reported gout attacks. Those safety reports weren't trials specifically designed to test gout prevention. Taken together, the findings don't support a confident promise about gout risk.
Tirzepatide and uric acid
Tirzepatide has stronger trial evidence for lowering the blood test number. A later analysis of SURMOUNT-1, published in Annals of the Rheumatic Diseases in 2026, examined 2,539 adults with overweight or obesity without diabetes.
Over 72 weeks, uric acid fell by an average of 0.69–0.95 mg/dL across tirzepatide groups. The average drop was 0.18 mg/dL with placebo, a dummy treatment.
The trial wasn't designed to test gout treatment, so it doesn't settle whether tirzepatide reduces attacks. These findings also cannot tell whether it is better than semaglutide for someone with gout.
Why a gout flare can still happen
An April 18, 2026 report in AACE Endocrinology and Diabetes described a temporary rise in uric acid, and gout attacks, after weight loss with tirzepatide and semaglutide.
These were selected cases, so they can't tell how often this happens or prove that the medicines caused it. They support discussing flare monitoring during substantial weight loss.
Dehydration, meaning too little fluid in the body, is a separate concern. In a 2017 survey of 550 people with gout, about one in 20 identified it as a flare trigger. Those were patient reports, rather than proof of a cause.
The Wegovy label, revised June 2026, warns about kidney injury after fluid loss from nausea, vomiting or diarrhea. Persistent stomach symptoms deserve clinical review, particularly when fluid intake is difficult.
The semaglutide side effects guide explains those symptoms. The semaglutide and kidney disease guide covers why kidney history also matters.
What a gout history changes in the visit
A useful visit covers recent attacks, the latest uric acid result, kidney function and the full medication list. It also covers whether nausea or vomiting has made eating and drinking difficult. These details help the clinician plan follow-up alongside weight treatment.
The 2020 American College of Rheumatology gout guideline recommends a blood urate target below 6 mg/dL for people receiving urate-lowering treatment. That means medicines prescribed to bring uric acid down. Allopurinol is one example, and the guideline supports continuing this treatment long term.
Semaglutide hasn't been shown to replace those medicines. Weight management can be part of gout care, while the gout clinician remains responsible for medication changes and the flare plan. A changing weight or blood test result is a reason to review that plan together.
What compounded semaglutide means here
Compounding means preparing a medication for a patient's prescription. Semaglutide and tirzepatide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which are different from an FDA-approved product: the formulations offered here are not FDA-approved.
The FDA's explanation, current as of June 22, 2026, describes how that status differs from a product reviewed before marketing. Studies of branded formulations don't establish identical results for every compounded preparation.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies.
The compounded semaglutide guide explains the preparation and prescription process. The prescriber sets the actual dose and follow-up plan, including how weight treatment fits with ongoing gout care.
